Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.
CiteScore:
CiteScore
SJR
SNIP
CiteScore排名
5.9
0.811
0.887
学科
排名
百分位
大类:Medicine 小类:General Medicine
75 / 636
88%
大类:Pharmacology, Toxicology and Pharmaceutics 小类:Pharmacology
Pub Date : 2024-12-18DOI: 10.7573/dic.2024-10-6Hema Sundaram, Beatriz Molina, Editta Buttura da Prato, Gabriel Siquier-Dameto, Michela Zazzaron, Clara Cigni, Franco Grimolizzi